

Research Article

Tauroursodeoxycholic acid prevents E22Q Alzheimer's A β toxicity in human cerebral endothelial cells

R. J. S. Viana^a, A. F. Nunes^a, R. E. Castro^a, R. M. Ramalho^a, J. Meyerson^b, S. Fossati^b, J. Ghiso^{b,c}, A. Rostagno^b and C. M. P. Rodrigues^{a,*}

^aiMed.UL, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, Lisbon 1649–019 (Portugal)

Fax: +351-21-794-6491, e-mail: cmprodriques@ff.ul.pt

^bDepartment of Pathology, New York University School of Medicine, New York, New York (USA)

^cDepartment of Psychiatry, New York University School of Medicine, New York, New York (USA)

Received 20 November 2008; received after revision 12 December 2008; accepted 12 January 2009

Online First 4 February 2009

Abstract. The vasculotropic E22Q mutant of the amyloid- β (A β) peptide is associated with hereditary cerebral hemorrhage with amyloidosis Dutch type. The cellular mechanism(s) of toxicity and nature of the A β E22Q toxic assemblies are not completely understood. Comparative assessment of structural parameters and cell death mechanisms elicited in primary human cerebral endothelial cells by A β E22Q and wild-type A β revealed that only A β E22Q triggered the Bax mitochondrial pathway of apoptosis. A β E22Q neither matched the fast oligomerization kinetics of A β 42 nor reached its predominant β -sheet

structure, achieving a modest degree of oligomerization with a secondary structure that remained a mixture of β and random conformations. The endogenous molecule tauroursodeoxycholic acid (TUDCA) was a strong modulator of A β E22Q-triggered apoptosis but did not significantly change the secondary structures and fibrillogenic propensities of A β peptides. These data dissociate the pro-apoptotic properties of A β peptides from their distinct mechanisms of aggregation/fibrillization *in vitro*, providing new perspectives for modulation of amyloid toxicity.

Keywords. Apoptosis, cerebral amyloid angiopathy, E22Q mutant A β peptide, mitochondria, TUDCA.

Introduction

Cerebral amyloid angiopathy (CAA), a common feature of Alzheimer's disease (AD), is an age-associated condition characterized by the deposition of amyloid peptides in cortical and leptomeningeal vessels, causing capillary disruption and endothelium dysfunction and playing a significant role in intracerebral hemorrhage [1–3]. Different proteins are associated with CAA (reviewed in [4, 5]). The most

common is amyloid- β (A β), which is the main component of the deposits seen in normal aging and sporadic AD that originates by processing of the amyloid precursor protein (APP) (reviewed in [6]). Of the several mutations identified in the APP gene, substitutions at residues flanking the A β region affect the rate of enzymatic APP processing and the production of A β 42, resulting in an early-onset AD phenotype [7]. On the contrary, mutations within the A β sequence, particularly at residues 21–23, generate A β variants Dutch, Iowa, Flemish, Arctic and Italian [8–11], which preferentially associate with CAA, hemorrhagic strokes and/or dementia. One of the

* Corresponding author.

most aggressive clinical phenotypes described in familial AD is associated with a glutamine to glutamic acid substitution at residue 22 (E22Q), found in a disorder known as hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWA-D) [8]. The disease is characterized by recurrent strokes and vascular dementia in the absence of neurofibrillar pathology, with fatal cerebral bleeding resulting from the massive amyloid deposition in leptomeningeal vessels and cortical arteries and arterioles (reviewed in [12]). Parenchymal mature plaques characteristic of AD are rare in this kindred, while diffuse preamyloid deposits are relatively frequent and show a remarkable relationship with age. They are more abundant in younger patients, suggesting that these lesions may develop into the less profuse mature fibrillar counterparts [13–15].

In general, A β mutants have been demonstrated to exert stronger toxicity than the wild-type counterparts in both neuronal [16] and cerebrovascular cells [9,17–19], although striking differences exist among the variants themselves. Differences in toxicity likely correlate with distinct structural properties conferred by the amino acid substitutions, which typically translate into enhanced fibrillogenic properties [20, 21]. These, in turn, influence the onset and aggressiveness of the respective clinical phenotypes (reviewed in [6]). One of the most-studied mutants is the aggressive intra-A β genetic variant E22Q. Following intraventricular injection in rats, this variant dramatically disrupts synaptic plasticity. Together with the Arctic (E22G) mutant, it is 100-fold more potent than wild-type A β 40 at inhibiting long-term potentiation [22]. The Dutch A β peptide has also been shown to exert potent effects on vessel wall cells, exhibiting anti-angiogenic properties [23] and inducing apoptosis in cerebral endothelial and smooth muscle cells, under conditions in which wild-type A β had no effects [9, 17–19]. Nevertheless, the cellular mechanism(s) by which A β mutants induce toxicity remains poorly understood and requires further investigation.

Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid known to play a key role in modulating the apoptotic threshold in various cell types by interfering with classical mitochondrial pathways of cell death [24]. Its antiapoptotic effects have been demonstrated in several pathological conditions, including different neurological disorders [25–29]. TUDCA modulates A β -induced cell death by inhibiting the mitochondrial pathway of apoptosis and enhancing survival signaling in rat cortical neurons [30]. Moreover, it can interfere with targets upstream of mitochondria, including cell cycle-related proteins E2F-1 and p53 [31], through functional modulation of nuclear steroid receptors [32]. These data strongly

suggest that TUDCA may also be beneficial in reducing other manifestations of brain amyloid toxicity, such as CAA.

Many studies have been devoted to elucidate the mechanisms of A β neurotoxicity. However, there is limited information available regarding the effect(s) of amyloid peptides on endothelial vessel wall cells that are in immediate contact with the vascular amyloid deposits in CAA. In this study, we compared aggregation/fibrillization properties, secondary structure, and cell death pathways of the Dutch variant and wild-type A β 40 and A β 42, both in the presence and absence of TUDCA. Our data dissociate the apoptotic properties of A β peptides in human cerebral endothelial cells and their distinct mechanisms of aggregation *in vitro*, while providing new perspectives for modulation of amyloid-induced apoptosis.

Materials and methods

Peptide synthesis. Synthetic wild-type A β 40 and A β 42 peptides as well as A β 40 peptide containing the E22Q substitution were synthesized by James I. Elliott at Yale University using *N*-*tert*-butyloxycarbonyl chemistry and then purified by reverse phase-high performance liquid chromatography on a Vydac C4 column (Western Analytical, Murrieta, CA) [9, 33]. Molecular masses were corroborated by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and concentration assessed by amino acid analysis. All peptides were supplied as single components eluted from the reverse-phase columns with experimental molecular masses of 4329.41 Da for A β 40 (theoretical mass, 4329.86 Da), 4514.24 Da for A β 42 (theoretical mass, 4514.10 Da) and 4328.80 Da for A β 40E22Q (theoretical mass, 4328.87 Da).

Peptide aggregation. Synthetic A β homologues were dissolved to 1 mM in hexafluoro-isopropanol (HFIP; Sigma Chemical Co., St. Louis, MO), a pre-treatment that breaks down β -sheet structures and disrupts hydrophobic forces leading to monodisperse A β preparations [34]. Following lyophilization to remove HFIP, peptides were subsequently solubilized in deionized water and added to an equal volume of a 2 \times concentrated phosphate-buffered saline (PBS), pH 7.4, to a final concentration of 1 mg/ml in 1 \times PBS. Peptides, in the presence or absence of 100 μ M TUDCA (Sigma), were either incubated at 37°C for up to 48 h for the aggregation studies or diluted into culture media at the required concentration for the toxicity experiments. For the aggregation studies, structural properties were assessed by Western blot

analysis, circular dichroism (CD) spectroscopy and Thioflavin T binding.

Peptide structural analysis. For the Western blot analysis, 200 ng aliquots of each peptide either freshly solubilized or after 24 and 48 h of aggregation, in the presence or absence of TUDCA, were separated on 16.5 % Tris-Tricine SDS-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, proteins were electrotransferred to nitrocellulose membranes (Hybond-ECL; GE Healthcare Life Sciences, Piscataway, NJ) using 10 mM 3-cyclohexylamino-1-propanesulfonic acid (Sigma) buffer, pH 11.0, containing 10 % (v/v) methanol, at 400 mA for 2 h. After blocking in 5 % nonfat milk in PBS containing 0.1 % Tween 20, the membranes were immunoreacted with a combination of mouse monoclonal anti-A β antibodies 4G8 (epitope: residues A β 18–22) and 6E10 (epitope: residues A β 3–8), both from Covance (Princeton, NJ), at a 1/3000 dilution each, followed by incubation with horseradish peroxidase (HRP)-labeled F(ab')₂ anti-mouse IgG (1/5000; GE Healthcare Life Sciences). Fluorograms were developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) and exposed to Hyperfilm ECL (GE Healthcare Life Sciences).

The secondary structure of A β peptides was estimated by CD spectroscopy as previously described [9, 33]. Spectra in the far-UV light (190–260 nm; bandwidth, 1 nm; intervals, 1 nm; scan rate, 60 nm/min) yielded by the different peptides at each time point of aggregation were recorded at 24 °C with a Jasco J-720 spectropolarimeter (Jasco Corp., Tokyo, Japan), using a 0.2-mm-path quartz cell and a peptide concentration of 1 mg/ml. For each sample, 15 consecutive spectra were obtained, averaged and baseline-subtracted. Results were expressed in terms of mean residue ellipticity (degree-cm² dmol⁻¹) [35].

Thioflavin T binding was assessed essentially as previously described [36, 37]. Six-microliter aliquots of each of the peptide aggregation time-point samples were added to 10 μ l of 0.1 mM Thioflavin T (Sigma) and 50 mM Tris-HCl buffer, pH 8.5 to a final volume of 200 μ l. Fluorescence was recorded after 300 s in a LS-50B luminescence spectrometer (Perkin Elmer, Waltham, MA) with excitation and emission wavelengths of 435 nm (slit width=10 nm) and 490 nm (slit width=10 nm), respectively. Each sample was analyzed in duplicate.

Culture of human brain microvascular endothelial cells. Primary human cerebral endothelial cells (HCEC; Cell Systems, Kirkland, WA) were grown in CS-C Complete Medium on dishes coated with Attachment Factor (Cell Systems), at 37 °C in a 5 %

CO₂ atmosphere. For cell death assays and immunocytochemistry, cells were plated at a density of 4 \times 10⁴ cells/ml. For immunoblotting, cells were plated at a density of 1 \times 10⁵ cells/ml. In all cases, cells were allowed to rest for 1 day prior to treatment with the A β peptides.

Induction of apoptosis. HFIP pre-treated A β peptides were dissolved to 500 μ M in PBS, as indicated above, and subsequently added to warm F12K Nutrient Mixture (Invitrogen/Gibco, Carlsbad, CA) supplemented with 1 % fetal bovine serum (FBS; Invitrogen/Gibco) to a 50 μ M final concentration. These freshly prepared peptide solutions were incubated with HCECs, cultured as described above, for 12 or 24 h. In co-incubation experiments, 100 μ M TUDCA was added to the cell cultures 12 h prior to the addition of A β peptides. As negative controls, cells were separately incubated either in the absence of amyloid peptides or with TUDCA alone. In all cases, attached cells were either fixed for Hoechst staining and immunocytochemistry analysis, or processed for viability assays. For Western blot analysis, attached and floating cells were combined prior to the preparation of cytosolic and mitochondrial protein fractions and subsequent protein extraction.

Measurement of cell death. Cell viability was measured by trypan blue exclusion and by the lactate dehydrogenase (LDH) viability assay (Sigma) according to the manufacturer's instructions. Apoptotic nuclei were detected by Hoechst labeling after cell fixation with 4 % formaldehyde in PBS, for 10 min at room temperature. Following incubation with Hoechst dye 33258 (Sigma) at 5 μ g/ml in PBS for 5 min, and PBS washes, slides were mounted with PBS:glycerol (3:1, v/v) and fluorescence visualized with an Axioskop fluorescence microscope (Carl Zeiss GmbH, Hamburg, Germany). Fluorescent nuclei were scored and categorized according to the condensation and staining characteristics of chromatin. Normal nuclei showed non-condensed chromatin dispersed over the entire nucleus. Apoptotic nuclei were identified by condensed and fragmented chromatin contiguous to the nuclear membrane, as well as nuclear fragmentation and presence of apoptotic bodies. Three random microscopic fields per sample of approximately 250 nuclei were counted and mean values expressed as the percentage of apoptotic nuclei.

Immunocytochemistry. After 24 h of exposure to the respective amyloid peptides, both in the presence and absence of TUDCA, HCECs were either directly processed for mitochondria labeling in live cells or

fixed in 4 % formaldehyde in PBS as above for the immunocytochemical evaluation of cytochrome *c* and Bax.

Staining of mitochondria in A β -challenged cells was performed by incubation for 30 min with 100 nM Red-Fluorescent MitoTracker Probe (Invitrogen/Molecular Probes, Eugene, OR) to allow for the selective incorporation of the dye and subsequent staining of the organelles. Immunofluorescence signals were evaluated using fluorescence microscopy as above. Bax mitochondrial immunocolocalization was performed with the Tyramide Signal Amplification Kit (Invitrogen/Molecular Probes), according to the manufacturer's instructions. Briefly, cells were fixed with 4 % formaldehyde as above, washed with PBS and incubated with 1 % blocking reagent, 0.1 % Triton X-100 for 1 h, at room temperature. Incubation with mouse monoclonal anti-Bax antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (1:50 in blocking solution; overnight, 4°C) was followed by HRP-conjugated goat anti-mouse IgG (Bio-Rad Laboratories, Hercules, CA) (1:200; 1 h, room temperature). Cells were subsequently incubated with Alexa Fluor 350-labeled tyramide (1:100 in amplification buffer/0.0015 % H₂O₂; 10 min, room temperature), washed with PBS and mounted in PBS: glycerol (3:1, v/v). Fluorescence was visualized as above.

For cytochrome *c* immunostaining, after A β challenge and fixation, HCECs were incubated for 1 h with PBS containing 0.3 % Triton X-100 (PBST) and 20 mg/ml bovine serum albumin (BSA). This was followed by 2 h incubation with monoclonal antibody anti-cytochrome *c* (BD Biosciences, Franklin Lakes, NJ; 1:200 in PBST containing 5 mg/ml BSA) and 1 h reaction with Alexa Fluor 488 conjugated anti-mouse secondary antibody (Invitrogen; 1:200 in PBST with 5 mg/ml BSA). Slides were mounted with Dapi-containing Mounting Medium (Vectashield, Burlingame, CA) and images acquired in a Nikon Eclipse E-800 Deconvolution Microscope, using Image-Pro Plus software (Media Cybernetics, Silver Springs, MD) and Autodeblur (AutoQuant Imaging, Inc., Water-vliet, NY) for deconvolution. Specificity of immune detection was assessed by omission of the primary antibody.

Bax translocation and cytochrome *c* release. Subcellular distribution of Bax and cytochrome *c* in amyloid-challenged HCECs was determined using mitochondrial and cytosolic protein extracts. Briefly, cells were collected by centrifugation at 600 *g* for 5 min at 4°C. The pellets were washed once in ice-cold PBS and resuspended with 3 volumes of isolation buffer (20 mM HEPES/KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT)

supplemented with Complete protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Mannheim, Germany), in 250 mM sucrose. After chilling on ice for 15 min, cells were disrupted by 40 strokes of a glass homogenizer, and homogenates were centrifuged twice at 2500 *g* for 10 min at 4°C to remove unbroken cells and nuclei. The supernatants were further centrifuged at 12 000 *g* for 30 min at 4°C, and the pellets containing the mitochondrial fraction resuspended in isolation buffer and frozen at -80°C. For cytosolic proteins, the 12 000 *g* supernatants were collected, filtered sequentially through 0.2 μ m and 0.1 μ m Ultrafree MC filters (Millipore, Bedford, MA) to remove other cellular organelles, and frozen at -80°C. Protein concentrations of the subcellular fractions were determined using the Bio-Rad protein assay kit according to the manufacturer's specifications. For Western blot detection of cytochrome *c* and Bax, typically 10 μ g of mitochondrial and 50 μ g of cytosolic proteins were separated on 15 % SDS-PAGE and transferred onto nitrocellulose membranes. After sequentially blocking with 15 % H₂O₂ and 5 % non-fat milk (1 h, room temperature), membranes were separately incubated overnight at 4°C with mouse monoclonal anti-Bax (Santa Cruz Biotechnology) and anti-cytochrome *c* (PharMingen, San Diego, CA) diluted 1:500, and 1:2000, respectively. Finally, immunoblots were incubated with HRP-conjugated secondary antibodies (Bio-Rad Laboratories; 1:5000, 3 h, room temperature) and processed for chemiluminescence detection using the SuperSignal Chemiluminescent Substrate (Thermo Scientific). Mitochondrial contamination of the cytosolic protein extracts was assessed with cytochrome *c* oxidase II (Cox II; Santa Cruz Biotechnology; 1:200). Cox II and β -actin (Sigma; 1:25 000) were used as loading controls for mitochondrial and cytosolic fractions, respectively.

Statistical analysis. Statistical analysis was performed using GraphPad InStat version 3.00 (Graph-Pad Software) for the analysis of variance and Bonferro-ni's multiple comparison tests. Values of $p < 0.05$ were considered significant.

Results

TUDCA does not affect A β peptide aggregation and secondary structure. It has been postulated that A β toxicity correlates with peptide aggregation propensity. Based on our previous findings demonstrating an inhibitory role of TUDCA on A β neurotoxicity, we studied its effect on the aggregation/fibrillization properties of the Dutch variant comparing with wild-type A β 40 and A β 42. As indicated in Figure 1a, wild-




Figure 1. Structural studies of wild-type and Dutch-variant A β peptides. HFIP-treated peptides at 1 mg/ml in PBS were aggregated at 37°C for up to 48 h. Peptide aggregation/fibrillization propensity as well as secondary structure were analyzed both in the presence and absence of 100 μ M TUDCA. (a) Oligomerization of wild-type and Dutch-variant peptides assessed by Western blot probed with a combination of monoclonal anti-A β antibodies 4G8 and 6E10 after separation on 16.5% Tris-Tricine SDS-PAGE. (b) Fibrillization of wild-type and Dutch-variant peptides estimated by fluorescence evaluation (excitation/emission wavelengths 435 nm/490 nm, respectively) after Thioflavin T binding. Solid lines, A β peptides alone; broken lines, A β peptides in the presence of TUDCA. (c) Secondary structure of wild-type and Dutch-variant peptides assessed through the respective spectra in the far-UV light (190–260 nm) in a Jasco J-720 spectropolarimeter via a 0.2 mm-path quartz cell, at 24 (top) and 48 h (bottom) of aggregation. Blue, A β peptides alone; red, A β peptides in the presence of TUDCA; green, TUDCA alone.

type A β 40 remained mostly monomeric up to 48 h of incubation, with the appearance of only faint dimeric bands on Western blot analysis at this time point. In contrast, as expected, A β 42 showed high tendency to aggregate. Dimers and even faint tetrameric species were observed immediately after solubilization, whereas high molecular mass aggregates were readily visible at 24 h and accentuated at 48 h. A β E22Q showed an intermediate behavior with the formation of SDS-resistant oligomeric assemblies clearly noticeable at 48 h incubation but of lower molecular masses than those of A β 42. Notably, in all cases, co-incubation with TUDCA resulted in no significant changes in the aggregation properties of the different peptides. The effect of TUDCA on the fibrillogenic propensity of the peptides was assessed by Thioflavin T binding. Co-incubation with TUDCA did not modify the inherent properties of each peptide (Fig. 1b). In fact, A β 42 continued to express the highest fluorescence values, while A β 40 levels remained negligible even at 48 h. A β E22Q showed an intermediate behavior, in agreement with the aggregation pattern shown in Figure 1a. Secondary structure analysis by CD spec-

troscopy illustrated both the different structural characteristics of the peptides and the lack of effect of TUDCA (Fig. 1c). The initial A β 40 structure showed a minimum at 198 nm, characteristic of unordered conformations. Within 48 h of incubation, the peptide acquired a β -sheet-rich structure showing the typical minimum at 218 nm in the CD scan. A β 42 showed a predominantly β -sheet conformation even immediately after solubilization. A β E22Q exhibited an intermediate structural configuration, in agreement with the data illustrated in Figure 1a and b, with a mixture of random and β -sheet components when freshly solubilized and an increase in the β -sheet component at 48 h. However, A β E22Q did not achieve the predominant β -sheet conformation of the A β 42 in the time frame of the experiments. Corroborating the Western blot and Thioflavin T data, co-incubation with TUDCA did not induce conformational changes in the secondary structures of any of the A β peptides studied.

TUDCA inhibits A β E22Q-induced apoptosis in brain microvascular endothelial cells. Morphologic evalua-

tion of apoptosis induced by A β peptides in HCEC was performed by fluorescence microscopy following Hoechst staining (Fig. 2a). The results showed that nuclear fragmentation was differentially triggered by A β peptides, starting at 12 h of treatment, with a maximum at 24 h, under the conditions tested. Interestingly, the A β E22Q variant was very aggressive in HCECs, increasing apoptosis by almost threefold compared to controls ($p < 0.001$), in contrast to wild-type A β 40 and A β 42, which had almost no effect (Fig. 2b). Consistent with its vasculotropic properties, A β E22Q did not significantly increase cell death in primary rat cortical neurons (unpublished observations). TUDCA was highly effective at modulating A β E22Q-induced toxicity, significantly inhibiting peptide-induced nuclear fragmentation to levels comparable to controls ($p < 0.05$). Trypan blue dye exclusion and LDH levels (data not shown) were in accordance with the morphological results. Detailed characterization of the structural assemblies of A β E22Q indicated that the induction of apoptosis correlated with the presence of peptide oligomers of low molecular mass and intermediate Thioflavin-binding capacity (Fig. 1). Notably, pre-treatment with TUDCA did not induce significant changes either in the peptide structure or in the aggregation/fibrillization propensity.

TUDCA prevents A β E22Q-induced mitochondrial Bax translocation and cytochrome *c* release. To further investigate the cell death pathways differentially triggered by A β peptides in HCECs, we sought to determine the specific involvement of the mitochondrial pathway of apoptosis. Our results showed that the A β E22Q mutant was very effective at triggering cytochrome *c* translocation from mitochondria to the cytosol when compared to A β 40 and A β 42 (Fig. 3), which exhibited almost negligible effects. This is consistent with the lack of ability of the wild-type peptides to induce major apoptotic changes in HCECs. Data on Bax translocation from the cytosol to mitochondria, assessed by Western blot, were in agreement with cytochrome *c* changes (Fig. 3). The role of TUDCA in preventing A β E22Q-induced, mitochondria-dependent cell death was assessed by immunofluorescence microscopy. We confirmed that incubation of HCECs with the A β E22Q mutant resulted in cytochrome *c* release from mitochondria as illustrated by strong cytoplasmic staining, which was mostly abolished by TUDCA (Fig. 4). In addition, our results demonstrated that TUDCA significantly reduced co-localization of Bax with mitochondrial markers after incubation of HCECs with A β E22Q (Fig. 5a). In fact, TUDCA reduced mitochondrial co-localization of Bax to control values (Fig. 5b; $p < 0.05$).




Figure 2. A β E22Q-induced apoptosis in HCECs is inhibited by TUDCA. Cells were incubated either with vehicle (control), 50 μ M of wild-type or Dutch-variant A β peptides, \pm 100 μ M TUDCA for 24 h. In co-incubation experiments, cells were pre-treated with TUDCA for 12 h and the bile acid was left in the culture medium with A β peptides. (a) Fluorescence microscopy of Hoechst staining shows condensed or fragmented nuclei indicative of apoptosis in control cells (a), and in cells exposed to TUDCA (b), A β 40 (c) and A β 42 (d). Nuclear condensation or fragmentation was markedly increased in cells incubated with A β E22Q (e), but less evident in cells exposed to A β E22Q plus TUDCA (f). (b) Histogram shows the percentage of apoptotic cells (mean \pm SEM) identified by condensed and fragmented chromatin contiguous to the nuclear membrane, as well as nuclear fragmentation and presence of apoptotic bodies, following Hoechst staining and fluorescence microscopy. $\dagger p < 0.001$ from control; $*p < 0.05$ from A β E22Q.

Discussion

Extensive CAA is the neuropathological hallmark of familial AD cases linked to intra-A β mutations. These A β genetic variants show potent vasculotropic properties and result in a predominant deposition of A β




Figure 3. A β E22Q-induced Bax translocation and cytochrome *c* release in HCECs. Cells were incubated either with vehicle (control), or 50 μ M wild-type or Dutch-variant A β peptides for 24 h. Mitochondrial and cytosolic protein fractions were extracted for Western blot analysis. Representative immunoblots of Bax and cytochrome *c* cellular distribution are shown. Cytochrome *c* oxidase II (Cox II) and β -actin were used as loading controls for mitochondrial and cytosolic fractions, respectively. Cyt *c*, cytochrome *c*.

peptides ending at position 40 [38–40]. These are also the species that target the vasculature in sporadic AD, in contrast with the primary association of A β 42 with the parenchymal deposits [41, 42].

Aggregation/fibrillization of A β plays a critical role in neurodegeneration. It is now considered that the transition from soluble monomeric species circulating under normal conditions to the oligomeric, protofibrillar and end-point fibrillar assemblies contribute significantly to disease pathogenesis. In particular, intermediate oligomeric and protofibrillar forms seem to display the most potent effects in neuronal cells, inducing synaptic disruption and neurotoxicity (reviewed in [43, 44]). In contrast, the abundance of mature amyloid plaques correlates poorly with AD severity [45, 46]. Mutants with accelerated formation of intermediate species and increased stability of these structures, such as the Arctic (E22G) variant, elicit an earlier and stronger effect on neuronal cells compared with wild-type peptides [21, 47]. In contrast, the effect of A β genetic variants on cerebral vessel wall cells, specifically on endothelial cells, has not been so well characterized. The E22Q peptide has been shown to




Figure 4. TUDCA inhibits A β E22Q-induced cytochrome *c* release in HCECs. Cells were incubated either with vehicle (control), 50 μ M of wild-type or Dutch-variant A β peptides, \pm 100 μ M TUDCA for 24 h. In co-incubation experiments, cells were pre-treated with TUDCA for 12 h and the bile acid was left in the culture medium with A β peptides. Fluorescence microscopy shows mitochondrial localization of cytochrome *c* in control cells (a) and in cells exposed to TUDCA (b), A β 40 (c) and A β 42 (d). Strong cytoplasmic staining was evident in cells incubated with A β E22Q (e). Notably, co-incubation with TUDCA mostly abolished the effect induced by the Dutch-variant peptide (f).

selectively exert deleterious effects on these cells, significantly increasing apoptotic responses in comparison to the wild-type A β 40 [9, 19]. Nevertheless, the nature of the amyloid assemblies inducing toxicity remains uncertain. In the present study, we characterized in detail the conformational properties of the E22Q peptide triggering apoptotic responses in HCECs and demonstrated its intermediate fibrillogenic/aggregation properties and content of β -sheet conformation compared with wild-type A β 40 and A β 42. At one extreme, A β 40 exhibited a virtual lack of oligomerization; at the other, A β 42 showed high molecular mass assemblies with strong fibrillar components. The absence of apoptosis resulting from endothelial challenge with both wild-type peptides suggests that the intermediate conformation of the E22Q oligomeric assemblies accounts for the potent, specific apoptotic effect of this genetic variant.

The limited high-order oligomerization/fibrillization observed in A β E22Q correlates well with the findings from nuclear magnetic resonance spectroscopy and molecular dynamics simulation studies, which highlight the effect of the mutation in fibril stabilization




Figure 5. TUDCA inhibits AβE22Q-induced Bax translocation to the mitochondria in HCECs. Cells were incubated either with vehicle (control), 50 μM of wild-type or Dutch-variant Aβ peptides, ± 100 μM TUDCA for 24 h. In co-incubation experiments, cells were pre-treated with TUDCA for 12 h and the bile acid was left in the culture medium with Aβ peptides. (a) Fluorescence microscopy shows co-localization of Bax (in blue) with the mitochondria (in red) in control cells (a), and in cells exposed to TUDCA (b), Aβ40 (c) and Aβ42 (d). Mitochondrial co-localization of Bax was markedly increased in cells incubated with AβE22Q (e), but less evident in cells exposed to AβE22Q plus TUDCA (f). (b) Histogram shows mean ± SEM percentage of co-localized cells. †*p* < 0.05 from control; **p* < 0.05 from AβE22Q.

[48, 49]. These studies indicate that the wild-type Aβ peptide, although mostly unstructured in solution, bears some regions exhibiting structural order and

protease resistance. A fragment stretching from amino acids 21 through 30 adopts a stable bend structure which appears to nucleate monomer folding [50]. The turn is stabilized by hydrophobic interactions between Val24 and Lys28 and by long-range electrostatic interactions between Lys28 and either Glu22 or Asp23. The computational studies predicted that the E22Q mutation would translate into destabilization of the turn and enhanced oligomerization propensity [51, 52], consistent with our findings. Also, a contributing factor to the nucleation propensity of the Dutch variant may be constituted by the depletion of the Glu22-Lys28 salt bridge as a consequence of the Glu-for-Gln substitution [52].

The major form of apoptosis in mammalian cells proceeds through the mitochondrial pathway, which involves mitochondrial outer membrane permeabilization and modulation by the Bcl-2 family of proteins. While some members of this family, typically located in the mitochondrial membrane, are potent inhibitors of apoptosis, others, including Bax, are pro-apoptotic and predominantly cytosolic (reviewed in [53]). Upon commitment to apoptosis, and after mitochondrial translocation, Bax undergoes conformational changes, oligomerizes and forms pores in the outer mitochondrial membrane, allowing the release of proteins, including apoptogenic cytochrome *c*, to the cytoplasm. These events facilitate downstream stages of the cell death cascades, leading to DNA fragmentation and formation of apoptotic bodies. Our data clearly demonstrate that AβE22Q is a strong inducer of the Bax pro-apoptotic mitochondrial pathway in HCEC and highlights its role in various downstream events. In fact, E22Q increased mitochondrial Bax and, consequently, cytosolic cytochrome *c*. As expected, both events were accompanied by downstream nuclear fragmentation. Although apoptosis indicators have not been investigated in HCHWA-D cases, it is noteworthy that studies in AD patients have demonstrated alterations in the expression of apoptosis-related genes, such as Bax [54, 55], suggesting that this process also takes place *in vivo*.

TUDCA is an endogenous bile acid that modulates the apoptotic threshold by interfering with classical mitochondrial pathways of cell death [24]. It has been previously shown that TUDCA is neuroprotective in pharmacological and transgenic mouse models of Huntington's disease [27, 56], reduces lesion volumes in rat models of ischemic and hemorrhagic stroke [28, 57], improves survival and function of nigral transplants in a rat model of Parkinson's disease [26], and partially rescues from mitochondrial dysfunction a Parkinson's disease model in *Caenorhabditis elegans* [58]. Additionally, TUDCA modulates Aβ-induced neuronal death by inhibiting the mitochondrial ma-

chinery and enhancing survival signaling [30], most likely through functional modulation of nuclear steroid receptors [32]. In particular, TUDCA was shown to mitigate primary neuron mitochondrial insufficiency and toxicity by inhibiting Bax translocation from cytosol to mitochondria [59] and subsequent downstream events ending in caspase activation, substrate cleavage and ultimately cell death. In this study, we show that TUDCA additionally protects brain microvascular endothelial cells from the apoptotic insult triggered by the potent vasculotropic E22Q peptide through suppression of Bax translocation, cytochrome *c* release and subsequent cell death. Notably, despite its potent anti-apoptotic role, TUDCA pre-treatment did not significantly alter the aggregation properties, fibrillogenic capacity or secondary structure of the A β peptides in our experimental *in vitro* paradigm. Future experiments should clarify whether TUDCA has any differential effect in the peptide fibrillization occurring in cell culture conditions.

The present data highlight a dichotomy between aggregation/fibrillization patterns and apoptotic properties of A β peptides in HCECs. Whether these observations downplay the role of high molecular mass structural assemblies in the induction of apoptosis, or simply indicate that TUDCA directly affects upstream pathways remains to be elucidated. It is conceivable that TUDCA may bind to the monomers/small oligomers of the A β peptides, affecting their capability to insert into lipid bilayers and form channels [60, 61]. Alternatively, as a cholesterol-derived molecule, TUDCA may insert into cellular membranes [62, 63], thus preventing the subsequent insertion of A β . Certainly, further studies are needed to identify the exact targets of TUDCA; nevertheless, this work provides new perspectives for the modulation of amyloid-induced toxicity in CAA, presenting new targets for therapeutic interventions.

Acknowledgements. This work was supported by grant PTDC/BIA-BCM/67922/2006 from Fundação para a Ciência e a Tecnologia (FCT), Lisbon, Portugal; NIH grants NS051715 and AG10491; and the American Heart Association. R.J.S.V. is the recipient of a PhD fellowship from FCT, Portugal (BD/30467/2006); A.F.N., R.E.C. and R.M.R. are recipients of postdoctoral fellowships from FCT, Portugal (BPD/34603/2007, BPD/30257/2006 and BPD/40623/2007, respectively).

- 1 Rensink, A. A., de Waal, R. M., Kremer, B. and Verbeek, M. M. (2003) Pathogenesis of cerebral amyloid angiopathy. *Brain Res. Brain Res. Rev.* 43, 207–223.
- 2 Coria, F. and Rubio, I. (1996) Cerebral amyloid angiopathies. *Neuropathol. Appl. Neurobiol.* 22, 216–227.
- 3 Vinters, H. V. (1987) Cerebral amyloid angiopathy. A critical review. *Stroke* 18, 311–324.
- 4 Yamada, M. (2000) Cerebral amyloid angiopathy: an overview. *Neuropathology* 20, 8–22.
- 5 Revesz, T., Ghiso, J., Lashley, T., Plant, G., Rostagno, A., Frangione, B. and Holton, J. L. (2003) Cerebral amyloid angiopathies: a pathologic, biochemical and genetic view. *J. Neuropathol. Exp. Neurol.* 62, 885–898.
- 6 Ghiso, J. and Frangione, B. (2002) Amyloidosis and Alzheimer's disease. *Adv. Drug Deliv. Rev.* 54, 1539–1551.
- 7 Selkoe, D. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 399, 23–31.
- 8 Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T., Luyendijk, W. and Frangione, B. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science* 248, 1124–1126.
- 9 Miravalle, L., Tokuda, T., Chiarle, R., Giaccone, G., Bugiani, O., Tagliavini, F., Frangione, B. and Ghiso, J. (2000) Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. *J. Biol. Chem.* 275, 27110–27116.
- 10 Hendriks, L., van Duijn, C. M., Cras, P., Cruts, M., Van Hul, W., van Harskamp, F., Warren, A., McInnis, M. G., Antonarakis, S. E., Martin, J. J. et al. (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. *Nat. Genet.* 1, 218–221.
- 11 Grabowski, T. J., Cho, H. S., Vonsattel, J. P., Rebeck, G. W. and Greenberg, S. M. (2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. *Ann. Neurol.* 49, 697–705.
- 12 Zhang-Nunes, S. X., Maat-Schieman, M. L., van Duinen, S. G., Roos, R. A., Frosch, M. P. and Greenberg, S. M. (2006) The cerebral beta-amyloid angiopathies: hereditary and sporadic. *Brain Pathol.* 16, 30–39.
- 13 Maat-Schieman, M. L., Yamaguchi, H., van Duinen, S. G., Natte, R. and Roos, R. A. (2000) Age-related plaque morphology and C-terminal heterogeneity of amyloid beta in Dutch-type hereditary cerebral hemorrhage with amyloidosis. *Acta Neuropathol.* 99, 409–419.
- 14 Natte, R., Maat-Schieman, M. L., Haan, J., Bornebroek, M., Roos, R. A. and van Duinen, S. G. (2001) Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. *Ann. Neurol.* 50, 765–772.
- 15 Maat-Schieman, M., Roos, R. and van Duinen, S. (2005) Hereditary cerebral hemorrhage with amyloidosis-Dutch type. *Neuropathology* 25, 288–297.
- 16 Murakami, K., Irie, K., Morimoto, A., Ohigashi, H., Shindo, M., Nagao, M., Shimizu, T. and Shirasawa, T. (2003) Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. *J. Biol. Chem.* 278, 46179–46187.
- 17 Van Nostrand, W. E., Melchor, J. P., Cho, H. S., Greenberg, S. M. and Rebeck, G. W. (2001) Pathogenic effects of D23N Iowa mutant amyloid beta-protein. *J. Biol. Chem.* 276, 32860–32866.
- 18 Davis, J. and Van Nostrand, W. E. (1996) Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. *Proc. Natl. Acad. Sci. USA* 93, 2996–3000.
- 19 Eisenhauer, P. B., Johnson, R. J., Wells, J. M., Davies, T. A. and Fine, R. E. (2000) Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant. *J. Neurosci. Res.* 60, 804–810.
- 20 Wisniewski, T., Ghiso, J. and Frangione, B. (1991) Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. *Biochem. Biophys. Res. Commun.* 179, 1247–1254.
- 21 Nilsberth, C., Westlund-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Sten, C., Luthman, J., Teplow, D. B., Younkin, S. G. et al. (2001) The 'Arctic' APP

- mutation (E693G) causes Alzheimer's disease by enhanced A β protofibril formation. *Nat. Neurosci.* 4, 887–893.
- 22 Klyubin, I., Walsh, D. M., Cullen, W. K., Fadeeva, J. V., Anwyl, R., Selkoe, D. J. and Rowan, M. J. (2004) Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation *in vivo*. *Eur. J. Neurosci.* 19, 2839–2846.
 - 23 Paris, D., Ait-Ghezala, G., Mathura, V.S., Patel, N., Quadros, A., Laporte, V. and Mullan, M. (2005) Anti-angiogenic activity of the mutant Dutch A(β) peptide on human brain microvascular endothelial cells. *Brain Res. Mol. Brain Res.* 136, 212–230.
 - 24 Rodrigues, C. M. P., Fan, G., Ma, X., Kren, B. T. and Steer, C. J. (1998) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. *J. Clin. Invest.* 101, 2790–2799.
 - 25 Macedo, B., Batista, A. R., Ferreira, N., Almeida, M. R. and Saraiva, M. J. (2008) Anti-apoptotic treatment reduces trans-thyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. *Biochim. Biophys. Acta* 1782, 517–522.
 - 26 Duan, W. M., Rodrigues, C. M. P., Zhao, L. R., Steer, C. J. and Low, W. C. (2002) Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. *Cell Transplant.* 11, 195–205.
 - 27 Keene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J. and Low, W. C. (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. *Proc. Natl. Acad. Sci. USA* 99, 10671–10676.
 - 28 Rodrigues, C. M. P., Solá, S., Nan, Z., Castro, R. E., Ribeiro, P. S., Low, W. C. and Steer, C. J. (2003) Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. *Proc. Natl. Acad. Sci. USA* 100, 6087–6092.
 - 29 Colak, A., Kelten, B., Sagmanligil, A., Akdemir, O., Karaglan, A., Sahan, E., Celik, O. and Barut, S. (2008) Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. *J. Clin. Neurosci.* 15, 665–671.
 - 30 Solá, S., Castro, R. E., Laires, P. A., Steer, C. J. and Rodrigues, C. M. P. (2003) Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. *Mol. Med.* 9, 226–234.
 - 31 Ramalho, R. M., Ribeiro, P. S., Solá, S., Castro, R. E., Steer, C. J. and Rodrigues, C. M. P. (2004) Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. *J. Neurochem.* 90, 567–575.
 - 32 Solá, S., Amaral, J. D., Borralho, P. M., Ramalho, R. M., Castro, R. E., Aranha, M. M., Steer, C. J. and Rodrigues, C. M. P. (2006) Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis. *Mol. Endocrinol.* 20, 2292–2303.
 - 33 Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A. and Frangione, B. (2004) Systemic catabolism of Alzheimer's A β 40 and A β 42. *J. Biol. Chem.* 279, 45897–45908.
 - 34 Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A. and LaDu, M. J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *J. Biol. Chem.* 277, 32046–32053.
 - 35 Kelly, S. M., Jess, T. J. and Price, N. C. (2005) How to study proteins by circular dichroism. *Biochim. Biophys. Acta* 1751, 119–139.
 - 36 Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J. and Teplow, D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. *J. Biol. Chem.* 274, 25945–25952.
 - 37 LeVine, H. 3rd. (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. *Methods Enzymol.* 309, 274–284.
 - 38 Shin, Y., Cho, H. S., Fukumoto, H., Shimizu, T., Shirasawa, T., Greenberg, S. M. and Rebeck, G. W. (2003) A β species, including IsoAsp23 A β , in Iowa-type familial cerebral amyloid angiopathy. *Acta Neuropathol.* 105, 252–258.
 - 39 Castano, E. M., Prelli, F., Soto, C., Beavis, R., Matsubara, E., Shoji, M. and Frangione, B. (1996) The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. *J. Biol. Chem.* 271, 32185–32191.
 - 40 Kumar-Singh, S., Cras, P., Wang, R., Kros, J. M., van Swieten, J., Lübke, U., Ceuterick, C., Serneels, S., Vennekens, K., Timmermans, J. P. et al. (2002) Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. *Am. J. Pathol.* 161, 507–520.
 - 41 Mori, H., Takio, K., Ogawara, M. and Selkoe, D. J. (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. *J. Biol. Chem.* 267, 17082–17086.
 - 42 Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K. and Iqbal, K. (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. *Arch. Biochem. Biophys.* 301, 41–52.
 - 43 Caughey, B. and Lansbury, P. T. (2003) Protofibrils, pores, fibrils and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu. Rev. Neurosci.* 26, 267–298.
 - 44 Walsh, D. M. and Selkoe, D. J. (2007) A beta oligomers – a decade of discovery. *J. Neurochem.* 101, 1172–1184.
 - 45 McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I. and Masters, C. L. (1999) Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* 46, 860–866.
 - 46 Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E. and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am. J. Pathol.* 155, 853–862.
 - 47 Whalen, B. M., Selkoe, D. J. and Hartley, D. M. (2005) Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. *Neurobiol. Dis.* 20, 254–266.
 - 48 Ma, B. and Nussinov, R. (2006) The stability of monomeric intermediates controls amyloid formation: A β 25–35 and its N27Q mutant. *Biophys. J.* 90, 3365–3374.
 - 49 Zheng, J., Jang, H., Ma, B., Tsai, C. J. and Nussinov, R. (2007) Modeling the Alzheimer A β 17–42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavities. *Biophys. J.* 93, 3046–3057.
 - 50 Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C. and Teplow, D. B. (2005) On the nucleation of amyloid beta-protein monomer folding. *Protein Sci.* 14, 1581–1596.
 - 51 Grant, M. A., Lazo, N. D., Lomakin, A., Condron, M. M., Arai, H., Yamin, G., Rigby, A. C. and Teplow, D. B. (2007) Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. *Proc. Natl. Acad. Sci. USA* 104, 16522–16527.
 - 52 Krone, M. G., Baumketner, A., Bernstein, S. L., Wyttenbach, T., Lazo, N. D., Teplow, D. B., Bowers, M. T. and Shea, J. E. (2008) Effects of familial Alzheimer's disease mutations on the folding nucleation of the amyloid beta-protein. *J. Mol. Biol.* 381, 221–228.
 - 53 Youle, R. J. and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. *Nat. Rev. Mol. Cell Biol.* 9, 47–59.
 - 54 Mattson, M. P. (2000) Apoptosis in neurodegenerative disorders. *Nat. Rev. Mol. Cell Biol.* 1, 120–129.
 - 55 Sajan, F. D., Martiniuk, F., Marcus, D. L., Frey, W. H., 2nd, Hite, R., Bodayo, E. Z. and Freedman, M. L. (2007) Apop-

- totic gene expression in Alzheimer's disease hippocampal tissue. *Am. J. Alzheimers Dis. Other Dement.* 22, 319–328.
- 56 Keene, C. D., Rodrigues, C. M. P., Eich, T., Linehan-Stieers, C., Abt, A., Kren, B. T., Steer, C. J. and Low, W. C. (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. *Exp. Neurol.* 171, 351–360.
 - 57 Rodrigues, C. M. P., Spellman, S. R., Solá, S., Grande, A. W., Linehan-Stieers, C., Low, W. C. and Steer, C. J. (2002) Neuroprotection by a bile acid in an acute stroke model in the rat. *J. Cereb. Blood Flow Metab.* 22, 463–471.
 - 58 Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C. et al. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in *Caenorhabditis elegans*. *J. Biol. Chem.* 280, 42655–42668.
 - 59 Rodrigues, C. M. P., Stieers, C. L., Keene, C. D., Ma, X., Kren, B. T., Low, W. C. and Steer, C. J. (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. *J. Neurochem.* 75, 2368–2379.
 - 60 Jang, H., Zheng, J., Lal, R. and Nussinov, R. (2008) New structures help the modeling of toxic amyloid-beta ion channels. *Trends Biochem. Sci.* 33, 91–100.
 - 61 Jang, H., Zheng, J. and Nussinov, R. (2007) Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. *Biophys. J.* 93, 1938–1949.
 - 62 Guldutuna, S., Zimmer, G., Imhof, M., Bhatti, S., You, T. and Leuschner, U. (1993) Molecular aspects of membrane stabilization by ursodeoxycholate. *Gastroenterology* 104, 1736–1744.
 - 63 Rodrigues, C. M. P., Solá, S., Sharpe, J. C., Moura, J. J. and Steer, C. J. (2003) Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. *Biochemistry* 42, 3070–3080.

To access this journal online:
<http://www.birkhauser.ch/CMLS>
